Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market

Q: How long will it take to read this news story?

The story "Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market" has 461 words across 18 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market" was covered 5 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 225 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #26367744</li><li>URL: https://chronographically.beamstart.com/news/zydus-lifesciences-granules-glenmark-nifty-1740384</li></ul>

Business Standard Logo Business Standard 5h ago

Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market - Business Standard

Quick Summary:

Nifty Pharma among others has gained 0.8 per cent in trade, logging an intra-day high at 20,550.

As per the filing, four lawsuits, which included claims related to both generic Zetia and Vytorin, were subsequently remanded to the jurisdictions in which they were originally filed.

Senn develops and manufactures, Peptides and Peptides based applications for its global customers, providing contract research, development, and manufacturing services.